PARP Inhibitors- Competitive Landscape, Market and Pipeline Analysis, 2017

    PARP Inhibitors- Competitive Landscape, Market and Pipeline Analysis, 2017
    Date: 01 Nov, 2017
    Type:
    Pages: 157
    Geography: Global
    Code: DISR0017
    Delivery Timeline: 24 Hours

    DelveInsight’s report on “PARP Inhibitors- Competitive Landscape, Pipeline and Market Analysis, 2017” provides extensively provides details around the 3 marketed products in this class. This report further provides information on the therapeutic development of more than 10+ pipeline drugs at various stages covering Phase III, Phase II, Phase I and Pre-clinical therapeutics and contains a comparative assessment by monotherapy, route of administration and molecule type. The report further covers the 5+ dormant products in this space.

    The report provides therapeutic details of the marketed product along with their historical and forecasted sales till 2022. Comparative analysis of marketed and emerging (Phase III) drugs based on attribute analysis has been done in this report that helps in the understanding market positioning of each drug. The report further provides PARP inhibitors market and class share evolution. 

    Comparative analysis of pipeline drugs at various stages and their therapeutic assessment by product type and molecule type provides additional and vital details of the pipeline drugs. The report also provides the market drivers and barriers for PARP Inhibitors. Information on various technologies involved in the development of pipeline therapeutics along with all the collaborations and agreements of the respective company brings added the advantage of this report. Patent and Financing details related to the products are also provided.

    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

     

    • Report Highlights
    • Executive Summary
    • Collaboration, Acquisitions and Licensing
    • Overview
    • Poly (ADP-Ribose) Polymerase
    • Structure and Function of PARP1
    • PARP Homologs
    • Functions of PARP
    • Role in DNA Repair
    • Function in Chromatin Remodeling
    • Effects on Transcription Factors and Epigenetic Factors
    • PARP Inhibitor
    • Market Overview
    • Comparative Analysis of Pipeline & Marketed Products
    • Marketed Drug Candidate Profiles
    • Zejula: Tesaro
    • Product Description
    • Research and Development
    • Zejula Heat Map
    • Product Development Activities
    • Zejula Heat Map
    • Forecasted Sales for Zejula
    • Zejula Analyst Insights
    • Lynparza: AstraZeneca
    • Product Description
    • Research and Development
    • Product Development Activities
    • Lynparza Heat Map
    • Historical and Forecasted Sales for Lynparza
    • Lynparza Analyst Insights
    • Rubraca: Clovis Oncology
    • Product Description
    • Research and Development
    • Product development activities
    • Rubraca Heat Map
    • Forecasted Sales for Rubraca
    • Rubarca Analyst Insights
    • Market Positioning of PARP Inhibitors
    • PARP Inhibitors Market Evolution
    • PARP Inhibitors Class Share Evolution
    • Pipeline Therapeutics
    • Comparative Analysis
    • Late Stage Products (Phase III)
    • Comparative Analysis
    • Veliparib: AbbVie
    • Product Description
    • Research and Development
    • Product Development Activities
    • Forecasted Sales for Veliparib
    • Veliparib Analyst Insights
    • Other Drug Profiles in detailed report
    • Mid Stage Products (Phase II)
    • Comparative Analysis
    • 2X-121: 2X Oncology
    • Product Description
    • Research and Development
    • Product Development Activities
    • Other Drug Profiles in detailed report
    • Early Stage Products (Phase I and IND)
    • Comparative Analysis
    • BGB-290: BeiGene
    • Product Description
    • Research and Development
    • Product Development Activities
    • Other Drug Profiles in detailed report
    • Pre-clinical Stage Products
    • Comparative Analysis
    • NT-125: NewGen Therapeutics
    • Product Description
    • Research and Development
    • Other Drug Profiles in detailed report
    • Therapeutic Assessment: Active Products
    • Assessment by Monotherapy Products
    • Assessment by Route of Administration
    • Assessment by Stage and Route of Administration
    • Dormant Products
    • Comparative Analysis
    • ANG-3186: Angion Biomedica
    • Product Description
    • Product Development Activities
    • Other Drug Profiles in detailed report
    • Discontinued Products
    • Comparative Analysis
    • Iniparib: Sanofi
    • Product Description
    • Research and Development
    • Product Development Activities
    • Other Drug Profiles in detailed report
    • Appendix
    • Report Highlights
    • Executive Summary
    • Collaboration, Acquisitions and Licensing
    • Overview
    • Poly (ADP-Ribose) Polymerase
    • Structure and Function of PARP1
    • PARP Homologs
    • Functions of PARP
    • Role in DNA Repair
    • Function in Chromatin Remodeling
    • Effects on Transcription Factors and Epigenetic Factors
    • PARP Inhibitor
    • Market Overview
    • Comparative Analysis of Pipeline & Marketed Products
    • Marketed Drug Candidate Profiles
    • Zejula: Tesaro
    • Product Description
    • Research and Development
    • Zejula Heat Map
    • Product Development Activities
    • Zejula Heat Map
    • Forecasted Sales for Zejula
    • Zejula Analyst Insights
    • Lynparza: AstraZeneca
    • Product Description
    • Research and Development
    • Product Development Activities
    • Lynparza Heat Map
    • Historical and Forecasted Sales for Lynparza
    • Lynparza Analyst Insights
    • Rubraca: Clovis Oncology
    • Product Description
    • Research and Development
    • Product development activities
    • Rubraca Heat Map
    • Forecasted Sales for Rubraca
    • Rubarca Analyst Insights
    • Market Positioning of PARP Inhibitors
    • PARP Inhibitors Market Evolution
    • PARP Inhibitors Class Share Evolution
    • Pipeline Therapeutics
    • Comparative Analysis
    • Late Stage Products (Phase III)
    • Comparative Analysis
    • Veliparib: AbbVie
    • Product Description
    • Research and Development
    • Product Development Activities
    • Forecasted Sales for Veliparib
    • Veliparib Analyst Insights
    • Other Drug Profiles in detailed report
    • Mid Stage Products (Phase II)
    • Comparative Analysis
    • 2X-121: 2X Oncology
    • Product Description
    • Research and Development
    • Product Development Activities
    • Other Drug Profiles in detailed report
    • Early Stage Products (Phase I and IND)
    • Comparative Analysis
    • BGB-290: BeiGene
    • Product Description
    • Research and Development
    • Product Development Activities
    • Other Drug Profiles in detailed report
    • Pre-clinical Stage Products
    • Comparative Analysis
    • NT-125: NewGen Therapeutics
    • Product Description
    • Research and Development
    • Other Drug Profiles in detailed report
    • Therapeutic Assessment: Active Products
    • Assessment by Monotherapy Products
    • Assessment by Route of Administration
    • Assessment by Stage and Route of Administration
    • Dormant Products
    • Comparative Analysis
    • ANG-3186: Angion Biomedica
    • Product Description
    • Product Development Activities
    • Other Drug Profiles in detailed report
    • Discontinued Products
    • Comparative Analysis
    • Iniparib: Sanofi
    • Product Description
    • Research and Development
    • Product Development Activities
    • Other Drug Profiles in detailed report
    • Appendix

    Table 1: Marketed and Pipeline products for PARP Inhibitors

    Table 2: Forecasted Sales for Zejula (2017-2023)

    Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

    Table 4: Forecasted Sales for Rubraca (2017-2023)

    Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

    Table 6: Total Drugs for PARP Inhibitors

    Table 7: Late Stage Products (Phase III)

    Table 8: Forecasted Sales for Veliparib (2018-2023)

    Table 9: Forecasted Sales for Talazoparib (2018-2023)

    Table 10: Mid  Stage Products (Phase II)

    Table 11: Early Stage Products (Phase I)

    Table 12: Pre-clinical Stage Products

    Figure 1: Structural and functional characteristics of PARP1

    Figure 2: PARP Family of Proteins

    Figure 3: Role of PARP1 in Base Excision Repair (BER)

    Figure 4: Role of PARP1 in Transcription Regulation

    Figure 5: PARP Inhibition

    Figure 6: Marketed and Pipeline products for PARP Inhibitors

    Figure 7: Forecasted Sales for Zejula (2017-2023)

    Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

    Figure 9: Forecasted Sales for Rubraca (2017-2023)

    Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

    Figure 11: Total Drugs for PARP Inhibitors

    Figure 12: Late Stage Products (Phase III)

    Figure 13: Forecasted Sales for Veliparib (2018-2023)

    Figure 14: Forecasted Sales for Talazoparib (2018-2023)

    Figure 15: Mid Stage Products (Phase II)

    Figure 16: Early Stage Products (Phase I)

    Figure 17: Pre-clinical Stage

    Figure 18: Assessment by Monotherapy

    Figure 19: Assessment by Route of Administration

    Figure 20: Assessment by Stage and Route of Administration

    Figure 21: Dormant Products

    Figure 22: Discontinued Products


    • 2X Oncology

    • AbbVie

    • BeiGene

    • Checkpoint Therapeutics

    • IMPACT Therapeutics

    • Jeil Pharmaceutical

    • Jiangsu HengRui Medicine

    • Jiangxi Qingfeng Pharmaceutical

    • and others...


    • Single User License
      $2,700.00
    • Site License
      $5,500.00
    • Global License
      $8,250.00

    Why Us?

    Diligent Market mission is to provide "insight across the value chain" to help organizations make important business decisions through the use and analysis of actionable market intelligence. It is our mission to provide the most effective results and services coupled with acute client care to create a long-lasting relationship with our clients.